Emodin reverses sorafenib resistance in hepatocellular carcinoma by inhibiting epithelial-mesenchymal transition via the Akt signaling pathway.

ABSTRACT:

Background

Sorafenib resistance poses a significant challenge in the management of advanced hepatocellular carcinoma (HCC). Therefore, understanding the mechanisms behind sorafenib resistance is crucial for reversing resistance and enhancing the therapeutic effect of this anti-cancer drug. In this study, the molecular mechanisms underlying the ability of emodin to reverse sorafenib resistance were examined in sorafenib-resistant Huh7 (Huh7SR) cells.

Methods

In this study, we successfully established a Huh7SR cell line that was subsequently divided into four treatment groups: control, sorafenib, emodin, and a combination of sorafenib and emodin. The cell viability, migration, invasion, colony formation capacity, and apoptosis of cells were assessed using the Cell Counting Kit

SUBMITTER: Wang Q 

PROVIDER: S-EPMC11833387 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature